|
4'-Substituted nucleoside analogs as anticancer drugs
|
1R01CA124952-01A2
|
$457,367
|
SECRIST, JOHN
|
SOUTHERN RESEARCH INSTITUTE
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
|
1R43CA132257-01A1
|
$140,983
|
MORGAN, Lee
|
DEKK-TEC, INC.
|
|
A behavioral trial for parents of childhood cancer survivors with neurobehavioral
|
1R03CA130731-01A1
|
$83,250
|
Patel, Sunita
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
A Drosophila Model for MEN2 and Sporadic MTCs
|
5R01CA084309-09
|
$236,780
|
Cagan, Ross
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
A Low-Dose Decitabine Strategy for Restoring Ovarian Cancer Sensitivity
|
1R21CA133877-01A1
|
$341,397
|
Matei, Daniela
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
A mouse model of TGFbeta1 and tumor immunosurveillance in Squamous cell cancer
|
5R01CA117957-03
|
$215,636
|
GLICK, ADAM
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er
|
5R21CA130343-02
|
$224,400
|
MILLER, VINCENT
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
A phase II study of IPI-504 in metastatic hormone refractory prostate cancer
|
1R21CA128352-01A1
|
$268,452
|
oh, william
|
DANA-FARBER CANCER INSTITUTE
|
|
A PILOT INVESTIGATION OF ETHNIC DISPARITIES IN PATIENT-INITIATED PREMATURE TREATM
|
5R03CA128470-02
|
$72,000
|
Adams, Swann
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
|
A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
|
5R01CA051578-16
|
$236,153
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
|
A Pull-Push Strategy for Lymphoma Immunotherapy
|
5K08CA105064-05
|
$128,547
|
Song, Wenru
|
BAYLOR RESEARCH INSTITUTE
|
|
A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon
|
1R21CA135595-01
|
$369,078
|
Camidge, Ross
|
UNIVERSITY OF COLORADO DENVER
|
|
A Transgenic Model for Prostate Tumor Immunity
|
5R01CA109339-05
|
$281,848
|
ADLER, ADAM
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Aberrant Crypt Foci as a Biomarker for Chemoprevention
|
5R01CA113681-03
|
$1
|
SINICROPE, FRANK
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-33S1
|
$104,604
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-33S2
|
$250,000
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
5P30CA016520-33
|
$7,326,647
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
ACOSOG Competing Renewal
|
2U10CA076001-12
|
$3,011,166
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
ACOSOG Competing Renewal
|
3U10CA076001-12S1
|
$342,900
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
3R01CA085915-08S1
|
$51,498
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
5R01CA085915-08
|
$311,663
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adherence Among Older Women with Breast Cancer
|
5K07CA109064-05
|
$136,080
|
GIORDANO, SHARON
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Adrenocortical Cancer and Thyroid Carcinomas: Models with Unique Properties
|
Z01 BC 010626
|
$388,228
|
Fojo, Antonio
|
CCR (NCI)
|
|
Adult Leukemia Research Center
|
3P01CA018029-33S1
|
$140,652
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Adult Leukemia Research Center
|
5P01CA018029-33
|
$4,943,916
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Advanced Anatomic and Functional Response Assessment in Lung Cancer
|
5R01CA125143-02
|
$355,300
|
Schwartz, Lawrence
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Advanced Therapeutic Platforms for Cancer Therapy
|
N43CO800067-000
|
$149,860
|
REDDY, RAM
|
NEXT GENERATION THERAPEUTICS, INC.:11507
|
|
AIDS and Cancer Specimen Resource Central Office and Data Coordinating Center
|
2U01CA096230-06
|
$718,223
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
AIDS Malignancy Clinical Trials Corsortium
|
3U01CA121947-03S1
|
$249,599
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Corsortium
|
3U01CA121947-03S2
|
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Corsortium
|
3U01CA121947-03S3
|
$250,067
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
AIDS Malignancy Clinical Trials Corsortium
|
5U01CA121947-03
|
$3,732,363
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Aldose Reductase-Like-1, a Novel Hepatocellular Carcinoma Drug Resistant Protein
|
5R21CA122327-02
|
$173,400
|
Cao, Deliang
|
SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
|
|
Alkyltransferase Inhibitors for Cancer Chemotherapy
|
5R01CA071976-13
|
$250,931
|
PEGG, ANTHONY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
|
5R01CA125153-03
|
$253,704
|
GANGJEE, ALEEM
|
DUQUESNE UNIVERSITY
|
|
alphaBeta-crystallin: A Novel Biomarker in Breast Cancer
|
5R21CA125181-02
|
$151,000
|
CRYNS, VINCENT
|
NORTHWESTERN UNIVERSITY
|
|
Altered Arachidonic Acid Balance and Colon Cancer
|
5R01CA114635-03
|
$311,403
|
Rosenberg, Daniel
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
American Academy of Cancer Education Annual Meetings - 2006, 2007, 2008
|
5R13CA126454-03
|
$19,420
|
VON GUNTEN, CHARLES
|
SAN DIEGO HOSPICE AND PALLIATIVE CARE
|
|
An anti-CD74 MAb-drug conjugate for B-cell malignancies
|
2R44CA108083-02A2
|
$492,190
|
GOVINDAN, SERENGULAM
|
IMMUNOMEDICS, INC.
|
|
AN EXPLORATORY STUDY TO IDENTIFY POTENTIAL SURROGATE ENDPOINT BIOMARKERS THAT ARE
|
N01CN095139-013
|
|
EUHUS, DAVID
|
UNIVERSITY OF TEXAS SW MED CTR/DALLAS
|
|
An Integrated Clinical Risk Assessment System for Chemotherapy and Myelotoxicity
|
1R43CA132503-01
|
$100,000
|
LANGHEIER, JASON
|
PROVENTYS, INC.
|
|
Analysis of AND-34 in human breast cancer
|
5R01CA114094-04
|
$229,749
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722001-002
|
$739,303
|
TURNER, GREGORY
|
MIDWEST RESEARCH INSTITUTE KANSAS CITY:1
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722002-002
|
$688,286
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE:1109097
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722003-002
|
$978,310
|
WANG, JENNIE
|
SRI INTERNATIONAL:1110101
|
|
Analysis of Patient Tumor Responses to Apo2L/TRAIL
|
5R01CA108888-03
|
$301,909
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Anatomic and Biologic Staging of Breast Disease with MRI
|
5R01CA069587-11
|
$434,608
|
Hylton, Nola
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
ANDROGEN SYNTHESIS INHIBITORS FOR PROSTATE CANCER
|
5R01CA027440-29
|
$316,811
|
BRODIE, ANGELA
|
UNIVERSITY OF MARYLAND BALTIMORE
|
|
Animal Model for Local Inflammation-Induced Breast Cancer
|
5R03CA117486-02
|
$75,750
|
NAKSHATRI, HARIKRISHNA
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
Annual Uterine Cancer Symposium
|
5R13CA113095-05
|
$971
|
LU, KAREN
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|